Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Community-acquired pneumonia,Acute bacterial sinusitis,Acute bacterial exacerbation of chronic bronchitis,Skin and skin structure infections (uncomplicated and complicated),Complicated intra-abdominal infections,Pelvic inflammatory disease,Urinary tract infections (complicated and uncomplicated),Prophylaxis of anthrax exposure,Plague,Empiric therapy in febrile neutropenia (off-label)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
400 mg intravenously once daily.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
12-15 hours (terminal elimination half-life; allows once-daily dosing; may be prolonged in renal impairment).
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Moxifloxacin undergoes sulfate conjugation (phase II metabolism) via sulfotransferases; it is not metabolized by cytochrome P450 enzymes. Approximately 20% is excreted unchanged in urine, and 25% as a glucuronide conjugate.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal (~20% unchanged, plus ~35% as glucuronide and sulfate conjugates), biliary/fecal (~25% unchanged and conjugates, total ~50% via feces).
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
~50% bound, primarily to serum albumin.
Low protein binding; 0–11% bound, primarily to albumin.
2.5–3.5 L/kg (indicates extensive tissue penetration, including lung and sinuses).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Oral: ~90% (bioequivalent to IV).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No dose adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min, use with caution.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No dose adjustment for Child-Pugh A or B; not recommended for Child-Pugh C due to lack of data.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Not recommended for patients <18 years due to risk of musculoskeletal adverse effects.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
No specific dose adjustment; monitor for QT prolongation and tendon effects.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Fluoroquinolones, including moxifloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients over 60 years of age, in those taking corticosteroids, and in kidney, heart, or lung transplant recipients. Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid use in patients with known myasthenia gravis.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Tendon injury (tendinitis, tendon rupture),Worsening of myasthenia gravis,Peripheral neuropathy, irreversible,Central nervous system effects (seizures, dizziness, confusion),QT prolongation (avoid in patients with known QTc prolongation, electrolyte abnormalities, or concomitant QT-prolonging drugs),Hypersensitivity/anaphylactic reactions,Clostridioides difficile-associated diarrhea,Photosensitivity/phototoxicity,Blood glucose disturbances (especially in diabetic patients on oral hypoglycemics or insulin),Avoid in patients with known aortic aneurysm or at risk for aortic aneurysm
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Known hypersensitivity to moxifloxacin or any fluoroquinolone,Pregnancy (animal data showing fetal harm; avoid unless benefit outweighs risk),Lactation (not recommended; may cause articular damage in nursing infants),Patients under 18 years of age (except for specific approved indications like anthrax),History of tendon disorders related to fluoroquinolone use,Uncorrected hypokalemia or hypomagnesemia (risk of QTc prolongation),Concomitant use with Class IA or Class III antiarrhythmics (QT prolongation risk)
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Avoid concurrent intake of dairy products (milk, yogurt, cheese), antacids containing calcium, magnesium, or aluminum, and supplements with calcium, iron, or zinc. Separate dosing by at least 2 hours before or 6 hours after these products. Caffeine intake should be limited as moxifloxacin may increase its effects (nervousness, insomnia). No other significant food interactions.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Moxifloxacin is contraindicated in pregnant women due to risk of fetal harm. Animal studies show arthropathy and cartilage damage in immature animals. Human data limited; avoid in all trimesters.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Moxifloxacin is excreted in human milk; M/P ratio unknown. Potential for infant joint damage. Avoid breastfeeding or discontinue drug.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No dose adjustment established. Pregnancy is a contraindication; therefore, use only if no alternative and benefit outweighs risk. No pharmacokinetic studies in pregnancy.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Moxifloxacin is a fourth-generation fluoroquinolone with enhanced activity against Gram-positive bacteria and anaerobes. It achieves high tissue penetration, including into the CSF. Avoid in patients with known QT prolongation or uncorrected hypokalemia due to risk of torsades de pointes. Use with caution in elderly patients and those with renal impairment; no dose adjustment needed for renal impairment but adjust for hepatic impairment (Child-Pugh C). Monitor for signs of tendinitis or tendon rupture, especially in patients over 60, those on corticosteroids, or with kidney, heart, or lung transplants. Administer intravenous infusion over 60 minutes to reduce risk of infusion-related reactions.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Take this medication exactly as prescribed; do not skip doses or stop early even if you feel better.,Contact your doctor immediately if you experience tendon pain, swelling, or rupture (especially in the Achilles tendon), or if you have muscle weakness, joint pain, or difficulty moving.,Avoid excessive sunlight or UV light exposure; use sunscreen and protective clothing as this drug can cause photosensitivity.,This drug may cause dizziness or lightheadedness; do not drive or operate machinery until you know how it affects you.,Drink plenty of fluids to stay hydrated, unless instructed otherwise by your doctor.,Inform your doctor if you have a history of seizures, QT prolongation, heart rhythm problems, or if you are taking antiarrhythmics or other drugs that affect heart rhythm.,Do not take with dairy products, antacids, or supplements containing calcium, magnesium, aluminum, or iron; these can reduce drug absorption. Take moxifloxacin at least 2 hours before or 6 hours after these products.,Report any signs of allergic reaction: rash, hives, difficulty breathing, swelling of face, lips, or throat.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Moxifloxacin, a fluoroquinolone antibiotic, and mefloquine, an antimalarial agent, both prolong the QT interval by inhibiting cardiac potassium channels (specifically hERG channels). When coadministered, there is an additive effect on QTc prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias. This interaction is particularly dangerous in patients with preexisting cardiac conditions, electrolyte imbalances, or bradycardia."
"Moxifloxacin, a fluoroquinolone antibiotic, can decrease the therapeutic efficacy of picosulfuric acid, a stimulant laxative used for bowel cleansing. This interaction likely occurs because moxifloxacin exhibits weak antagonistic activity at the 5-HT4 receptors in the gastrointestinal tract, partially counteracting the prokinetic and secretory effects mediated by picosulfuric acid. Consequently, patients may experience reduced bowel cleansing efficacy, potentially leading to inadequate colonic preparation for colonoscopy and increased risk of missed lesions."
"Dronedarone prolongs the QT interval by blocking multiple cardiac ion channels (primarily IKr). Moxifloxacin also prolongs the QT interval by blocking IKr. Coadministration leads to additive QTc prolongation, increasing the risk of torsades de pointes and ventricular arrhythmias. This risk is particularly elevated in patients with pre-existing electrolyte imbalances, bradycardia, or baseline QT prolongation."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is a Electrolyte that works by Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is: 400 mg intravenously once daily.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is classified as Category A/B. Moxifloxacin is contraindicated in pregnant women due to risk of fetal harm. Animal studies show arthropathy and cartilage damage in immature animals. Human data limited; avoid in . AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.